Clinical Trials Directory

Trials / Withdrawn

WithdrawnNCT03261726

Maintaining Cochlear Patency After VIIIth Nerve Surgery

Status
Withdrawn
Phase
N/A
Study type
Interventional
Enrollment
0 (actual)
Sponsor
Henry Ford Health System · Academic / Other
Sex
All
Age
Healthy volunteers
Accepted

Summary

Tumors arising from the VIIIth Nerve (vestibulo-cochlear nerve) typically present with progressive unilateral hearing loss and tinnitus. VIIIth Nerve tumors with documented growth on serial MRI scans typically lead to deafness in the affected ear over time. Radiation (Gamma Knife® or stereotactic radiosurgery) may preserve hearing in \~80% while surgery (middle cranial fossa or retrosigmoid approach) may preserve hearing in 16 - 40% of small tumors, although initial hearing preservation by both modalities may fail over time. Surgical resection via the translabyrinthine approach is the safest way to remove many of these tumors, but involves loss of all hearing. In all treatment modalities, the vascular supply (the labyrinthine artery, a terminal branch of AICA with no collaterals) to the cochlea is at risk. After devascularization, the cochlea frequently fills with fibrous tissue or ossifies (labyrinthitis ossificans), making it impossible to place a cochlear implant should it be required later. The incidence of this is 46% in our patients. This study seeks to determine the feasibility of preserving the cochlear duct with an obdurator so that patients undergoing translabyrinthine removal of VIIIth nerve tumors may retain the option of a cochlear implant at a later time.

Conditions

Interventions

TypeNameDescription
DEVICEMedEl Test Electrode PlacerThis study uses a sterile dummy (i.e., not working) cochlear implant electrode inserted at the time of tumor removal to keep the inner ear from scarring or filling with bone. The significance of this to you is that if you ever become eligible for a cochlear implant sometime after surgery, it may be possible to remove the dummy and insert a functioning cochlear implant.

Timeline

Start date
2017-08-04
Primary completion
2021-03-04
Completion
2021-03-04
First posted
2017-08-25
Last updated
2025-12-19

Locations

1 site across 1 country: United States

Regulatory

Source: ClinicalTrials.gov record NCT03261726. Inclusion in this directory is not an endorsement.